Bain Capital has completed the acquisition of DSM Sinochem Pharmaceuticals (DSP) from DSM and Sinochem Group, who each held an equity stake of 50%. 

DSM received about €250 million for its equity stake, excluding an earn-out (estimated at around €50m) and transaction costs. DSM anticipates a book profit of about €110 million on the transaction to be recognized in Q4 2018.

DSM expects to receive approximately €275 million in cash following closing, including repayment of debt and after transaction costs.